Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person ponatinib-resistant FLT3 mutants don't bind ponatinib
| Class:Id | FailedReaction:9702613 |
|---|
| _displayName | ponatinib-resistant FLT3 mutants don't bind ponatinib |
|---|
| _doRelease | TRUE |
|---|
| _timestamp | 2020-11-06 20:56:23 |
|---|
| authored | [InstanceEdit:9706566] Rothfels, Karen, 2020-11-06 |
|---|
| compartment | [Compartment:876] plasma membrane |
|---|
| created | [InstanceEdit:9702612] Rothfels, Karen, 2020-10-01 |
|---|
| disease | [Disease:1500689] cancer |
|---|
| edited | [InstanceEdit:9706566] Rothfels, Karen, 2020-11-06 |
|---|
| entityFunctionalStatus | [EntityFunctionalStatus:9702611] loss_of_function of ponatinib-resistant FLT3 mutants [plasma membrane] |
|---|
| input | [DefinedSet:9699527] ponatinib-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[ChemicalDrug:9669717] ponatinib [cytosol] |
|---|
| isChimeric | FALSE |
|---|
| literatureReference | [LiteratureReference:9702954] FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
[LiteratureReference:9695648] Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
[LiteratureReference:9699279] FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
[LiteratureReference:9699393] Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia |
|---|
| modified | [InstanceEdit:9703028] Rothfels, Karen, 2020-10-03
[InstanceEdit:9703080] Rothfels, Karen, 2020-10-05
[InstanceEdit:9704328] Rothfels, Karen, 2020-10-07
[InstanceEdit:9706570] Rothfels, Karen, 2020-11-06
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08 |
|---|
| name | ponatinib-resistant FLT3 mutants don't bind ponatinib |
|---|
| normalReaction |
|
|---|
| releaseDate | 2020-12-08 |
|---|
| reviewed | [InstanceEdit:9706568] Kazi, Julhash U, 2020-11-06 |
|---|
| reviewStatus | [ReviewStatus:9821382] five stars |
|---|
| species | [Species:48887] Homo sapiens |
|---|
| stableIdentifier | [StableIdentifier:9702616] R-HSA-9702613.2 |
|---|
| summation | [Summation:9703023] The following FLT3 mutants are resistant to inhibition by po... |
|---|
| (hasEvent) | [Pathway:9702614] ponatinib-resistant FLT3 mutants [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by ponatinib-resistant FLT3 mutants don't bind ponatinib (9702613)
